Best Life Sciences Companies in Newcastle Upon Tyne, United Kingdom
The 36 best Life Sciences companies in Newcastle Upon Tyne, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: QuantuMDx Group.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Newcastle Upon Tyne
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QuantuMDx Group Manufacturer of molecular diagnostic platforms and assays for infectious diseases | $57M | 49 mo ago | 98 98 → 53 (-46%) | Jonathan Halloran CEO & ex-Co-Founder | WordPressMySQLPHP+22 | Top 10M | 154 patents Patents concentrated in transport & manufacturing processes | — |
| 2 | Iksuda Therapeutics Developer of antibody drug conjugates for the treatment of solid cancers | $50M | 17 mo ago | 16 | David Simpson Co-Founder & CEO | GSAPAzureMicrosoft Advertising+12 | Top 10M | 29 patents Design and use of antibody-drug conjugates with novel linkers and co‑administration strategies | — |
| 3 | Newcells Biotech Developer of induced pluripotent stem cells derived organoid models for research application | $17M | 21 mo ago | 20 20 → 13 (-35%) | — | WordPressMySQLPHP+22 | Top 10M | 19 patents Microfluidic cell‑culture plates enabling scalable retinal organoid and airway epithelium models | 1 award |
| 4 | AMLo Biosciences Developer of a prognostic test for the early detection of cancer | $6M | 21 mo ago | 11 | Penny Lovat Co-Founder | — | — | 32 patents Diagnostic biomarkers and therapeutic antibodies for melanoma and squamous cell carcinoma | — |
| 5 | Biosignatures in vitro biomarker discovery and development | $6M | 85 mo ago | 18 | — | — | — | 6 patents Real-time endoscopic image enhancement and separation pattern analysis software | — |
| 6 | Nuchido Manufacturer of dietary supplements | $3M | 72 mo ago | 5 | Nichola Conlon Co-Founder & CEO | Cart FunctionalityShopifyShogun Page Builder+30 | Top 5M | 39 patents Nutraceutical anti‑aging formulations boosting NAD+ and protecting against oxidative/mitochondrial stress | — |
| 7 | NunaBio Provider of synthetic biology and biosensing platform for DNA products | $2M | 42 mo ago | 10 10 → 22 (+120%) | Eimer Tuite Co-Founder | — | — | 19 patents Enzymatic nucleic acid and gene synthesis platforms for custom DNA/RNA production | — |
| 8 | Aelius Biotech Provider of in vitro and human trial models for gut research | $2M | 17 mo ago | 2 | Peter Chater Co-Founder & CEO | WordPress Block EditorwpBakeryWordPress+28 | Top 50M | 13 patents Purified mucin biopolymers and related biological modeling devices for biotech applications. | — |
| 9 | CellRev Developer of cell cultivation technologies | $2M | 23 mo ago | 17 | Martina Miotto Co-Founder & Chief Scientific Officer | WordPressMySQLPHP+18 | Top 50M | — | — |
| 10 | PulmoBioMed Developer of non-invasive deep lung fluid collection technology. | $2M | 27 mo ago | 5 | Sterghios Moschos Founder | — | — | 2 patents Mouthpiece modules for exhaled breath collection in respiratory diagnostic devices | — |
| 11 | Atelerix Develops technology for storage and transportation of cells | $1M | 19 mo ago | 9 | Che Connon Co-Founder | — | — | 11 patents Biobanking and transport solutions for extracellular DNA/RNA, epitopes, and multicellular aggregates | 2 launchs · 1 award |
| 12 | GlycoScoreDx Developer of a diagnostic test for the detection of prostate cancer | $879K | 64 mo ago | 2 | Jennifer Munkley Founder | — | — | 5 patents Glycosylation-based biomarkers for prostate cancer detection and monitoring | — |
| 13 | Nonlinear Dynamics Proteomics and metabolomics analysis software | $750K | 170 mo ago | 691 | Will Dracup Founder | Cart FunctionalityWindows ServerPure CSS+20 | Top 10M | 6 patents Analyzing and modeling separation pattern representations for data mining and signal processing | — |
| 14 | Invenirex Developer of nucleic acid detection instruments | $637K | 10 mo ago | — | Dan Todd Founder & CEO | — | — | — | — |
| 15 | LightOx Provider of light activated treatment for oral cancer | $544K | 39 mo ago | 12 12 → 20 (+67%) | Mark Coles Co-Founder & Director | WordPressMySQLPHP+24 | Top 50M | 19 patents Epigenetic HDAC inhibitor therapeutics, gram‑positive antibacterial agents, and fluorescent imaging probes | — |
| 16 | Alcyomics Cell-based assay services for safety and efficacy assessment of novel compounds and drug | $490K | 73 mo ago | 10 10 → 14 (+40%) | — | WordPressMySQLPHP+13 | Top 50M | 25 patents Engineered innervated skin and cellular composites for in‑vitro biomedical testing | — |
| 17 | Syrona Health Digital women's health management software for employers and individuals | $200K | 53 mo ago | 5 | — | Headless UITailwind CSSReact+13 | Top 50M | — | — |
Top 12 Life Sciences companies in Newcastle Upon Tyne
#1
Series A · Newcastle Upon Tyne, England · founded 2012 · 16 employees$49.6Mraised▾
Developer of antibody-drug conjugates for the treatment of solid cancers including ovarian, lung, pancreas, cervix, and renal cell carcinoma. The company's product pipeline includes IKS01 which is in pre-clinical trials, IKS02, IKS03, IKS04 which are in the discovery phase.
- Mar 2025Series A$15M
- Jun 2021Series A$47M
- Jun 2012Seed$2.6M
#2
Series B · Newcastle Upon Tyne, England · founded 2014 · 20 employees$17Mraised▾
Developer of induced pluripotent stem cells derived organoid models for research application. The company has developed a range of off-the-shelf iPSC-derived products and currently has neural progenitor cells and cardiomyocytes. In addition, it provides custom reprogramming and differentiation services for biopharmaceutical companies and research institutions.
- Dec 2024Series B$1.5M
- Feb 2024Series B$3M
- Feb 2021Series B$7.4M
- Jan 2020Grant (prize money)$357.1K
#3
Seed · Newcastle Upon Tyne, England · founded 2021$636.8Kraised▾
Developer of nucleic acid detection instruments. The company revolutionize molecular analysis and propel scientific progress by developing real-time, ultra-sensitive nucleic acid detection instrumentation powered by the object-detection neural networks to accelerate life-sciences research.
- Nov 2025Seed$2.6M
- Nov 2025Grant (prize money)—
- Mar 2024Seed$636.8K
#4
Series A · Newcastle Upon Tyne, England · founded 2017 · 11 employees$5.7Mraised▾
Developer of a prognostic test for the early detection of cancer. The company provides a prognostic test for early detection of AJCC Stage I and Stage II melanoma. The company's product includes AMBLor, a diagnostic test that is based on two protein markers, AMBRA1 and loricrin (AMLo) present in the upper layer of the epidermis.
- Nov 2024Series A$2M
- Apr 2022Series A$3.2M
- Nov 2020Series A$2M
- Oct 2018Seed$494.1K
#5
Seed · Newcastle Upon Tyne, England · founded 2018 · 2 employees$2.2Mraised▾
Provider of in vitro and human trial models for gut research. They offer digestion, mucus, absorption, and microbiome models, along with colon kits. The company also provides bespoke project design and execution. These services support product development in the food, nutraceutical, biotech, and pharmaceutical industries.
- Apr 2025Seed$966.9K
- Nov 2023Seed$1.2M
#6
Seed · Newcastle Upon Tyne, England · founded 2017 · 9 employees$1.5Mraised▾
Atelerix has developed technology for storage of cells, especially for cryo shipping. The technology claims to provide following advantages Predictability and reliability in drug discovery models and for cells used as therapies, Customers can use cells and assays immediately on arrival, No need for cryopreservation, nor need for cytotoxic or animal-derived supplements, and Cells retain their natural state and are not damaged nor altered.
- Jan 2025Seed$935.5K
- Jan 2023Seed—
- Feb 2022Grant (prize money)$576.6K
- Sep 2020Grant (prize money)—
#7
Series A · Newcastle Upon Tyne, England · founded 2019 · 17 employees$1.8Mraised▾
Developer of cell cultivation technologies. The company's solutions include AggreGuard, an enzyme blend to prevent cell clumping, enabling scalable production for vaccines, therapies, cultivated meat, and biologics.
- Oct 2024Series A$14M
- Dec 2023Grant (prize money)$417.6K
- Dec 2023Series A$1.8M
- Feb 2022Series A$2.4M
#8
Series D · Newcastle Upon Tyne, England · founded 2008 · 98 employees$57.3Mraised▾
Manufacturer of molecular diagnostic platforms and assays for infectious diseases. The company's product portfolio centers on a rapid, portable PCR platform and a growing suite of multiplex molecular assays designed for point‑of‑care and near‑patient testing.
- Aug 2022Series D$19.2M
- Mar 2021Series C$15.2M
- Jan 2018Series B$12M
- Oct 2016Series A$2.5M
#9
Seed · Newcastle Upon Tyne, England · founded 2019 · 5 employees$1.8Mraised▾
{}
- 2024Grant (prize money)—
- Dec 2023Seed$2M
- Dec 2020Seed$996.3K
#10
Seed · Newcastle Upon Tyne, England · founded 2012 · 10 employees$2.4Mraised▾
Provider of synthetic biology and biosensing platform for DNA products. The company has two core business segments, one focused on biosensing across multiple industries and platforms, the second focused on DNA/gene production for use in cell therapies, vaccines, diagnostics, and gene therapies.
- Mar 2023Seed$2.4M
#11
Deadpooled · Newcastle Upon Tyne, England · founded 2007 · 18 employees$5.6Mraised▾
Biosignatures is a biotech company engaged in the research and development of in vitro biomarkers for disease diagnosis and prognosis. The company's product portfolio includes TigerPro (in development for monitoring and prognosis of prostate cancer), Renal Check (in development for diagnosis of renal cancer), BladderSafe (for diagnosis of bladder tumors), BiopSave (a blood diagnostic test for prostate cancer), CICERO (an image analysis tool for analyzing cystoscopy video data for identifying bladder cancer). Biosignature's products are centered around blood proteomics and its proprietary proteomics data analysis software that statistically analyzes and stratifies samples based on protein separation patterns.
- Aug 2019Series A$4.3M
- 2014Grant (prize money)—
- Oct 2008Seed$1.3M
#12
Seed · Newcastle Upon Tyne, England · founded 2016 · 5 employees$2.9Mraised▾
Manufacturer of dietary supplements. The company offers Nuchido TIME+ vegan supplements formulated with natural ingredients to support the cells, and natural ability and boost NAD+.
- Sep 2020Seed$1.3M
- Apr 2019Seed$719.3K
- Apr 2018Seed$601.3K
- Apr 2017Seed$321.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United Kingdom
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,508 United Kingdom-affiliated papers.
- Imperial College London70
- University College London67
- University of Cambridge54
- University of Edinburgh54
- University of Oxford48
- Gene4→31
- Population1→15
- Mutation1→13
- Chromatin1→11
- Mutant2→12
- Gene2→35
- Antimicrobial1→22
- Bacteria1→17
- Downregulation and upregulation1→17
- Antibody3→19
- Production (economics)3→14
- Antimicrobial4→14
- Agriculture9→18
- Sustainability1→10
- Food safety2→11
Where biotechnology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United Kingdom
United Kingdom biotechnology patent filing is accelerating — 35,956 filings from 8,000 assignees (2016–2025), led by Medimmune, Glaxo Group, UCL Business; annual filings 2688→3463.
- Medimmune2938
- Glaxo Group1582
- UCL Business1575
- UNIV Oxford Innovation1145
- Glaxosmithkline IP DEV997
- Medical RES Council945
- Cambridge Entpr859
- Kymab850
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.